Publication | Closed Access

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation

Hematological MalignancyTumor BiologyT315i MutationImmunologySelective InhibitorAdult T-cell Leukemia-lymphomaSystems BiologyMedicineRadiation OncologyMutated Bcr/ablCancer ResearchMyeloid Neoplasia